chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vaccine received Monday 04Jan, severe headache afterwards. Tuesday 05Jan, full body itchy rash. Unchanged with use of benadryl.; Vaccine received Monday 04Jan, severe headache afterwards. Tuesday 05Jan, full body itchy rash. Unchanged with use of benadryl.; This is a spontaneous report from a contactable healthcare professional. A 36-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL0142, expiry date not reported), via an unspecified route of administration in the left arm on 04Jan2021 14:00 at a single dose for COVID-19 immunisation. Medical history included depression and celiac disease. Concomitant medications included sertraline hydrochloride (ZOLOFT), omeprazole, calcium, and lactobacillus acidophilus (ACIDOPHILUS). The patient previously took amoxicillin, gluten and experienced allergies. It was reported that the patient had a vaccine received on Monday 04Jan2021, and experienced severe headache afterwards. On Tuesday 05Jan2021, the patient experienced full body itchy rash. These were unchanged with the use of Benadryl. Clinical outcome of the events was not recovered.
Upset stomach; skin lesions that turn into blisters might be Shingles; Skin lesions that turns to blister on her back and around belly button; Headache; Nausea; Chills; Muscle pain; Fatigue; Temparature of 99.5; A spontaneous report was received from a consumer, who was 42-year-old, female patient, who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced headache, nausea, upset stomach, muscle pain, fatigue, chills, fever 99.5 Fahrenheit(F), skin lesions and blisters on her back and around belly button, which could be shingles.  The patient's medical history was not provided by the reporter.  No relevant concomitant medications were reported.  On 30 DEC 2020, the patient received their first two planned doses of mRNA-1273 (batch number: unknown) for prophylaxis of COVID-19 infection.  On 30 DEC 2020, patient experienced headache, nausea, upset stomach, muscle pain, fatigue, chills and fever 99.5 F. The patient stated that the skin lesions on her back and around belly button had turned into blisters. The patient consulted her physician who prescribed acyclovir (for provisional shingles) and an unspecified ointment.   Treatment for the events included acetaminophen, acyclovir and an unspecified ointment.   Action taken with mRNA-1273 in response to the events was not applicable.  The outcome of events, headache, nausea, upset stomach, muscle pain, fatigue, chills, fever, were considered resolved on 30 DEC 2020.  The outcome of events, skin lesions, blisters on her back and around belly button and shingles were considered not resolved.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
12/27/2021 I began to feel unwell, sore throat fever, sinus, bad chest cough, loss of appetite, dizziness, and sever fatigue. Tested at home test positive. I adhered to the COVID protocols and received drop of herbal at door step. Was then able to receive care physical after the quarantine timeframes. Reported to the county health department of the outbreak. Not recovered, the chest cough, fatigue, sinus, cognitive fog is ongoing is the issue.
Patient received Moderna on 01/20/2021 and states that left arm was sore until Thursday, 01/21/2021. Patient woke up on 01/27/2021 with 45mm red knot at the injection site, with surrounding swelling. No tenderness to touch, but patient states pain is radiating to hand.  Site is warm to touch.
Immediate pain at vaccination site, which spread down the arm over the next several hours.  Eight hrs post-injection, fever of 101F, chills, severe myalgia
(R) arm with large area of redness, swelling & warmth to touch. Area size about baseball size.
Irregular rash/hives on torso, groin, inside of right elbow. Left eyelid, left side of my neck, inner thighs
This spontaneous report as received from a nurse practitioner refers to a male patient of unknown age. No information about the patient's medical history and concurrent conditions was reported. No concomitant medications were reported. On an unknown date, as a "kid", the patient might have been vaccinated with doses of MMR II (dose, frequency, lot #, expiration date and route of administration were not specified). On an unknown date (reported as recently), the patient had a MMR titer drawn that resulted low. On an unknown date, the patient experienced thalassemia. The outcome of the events was not reported. The relatedness between the events and MMR II was not provided. Additional information has been requested.
Itching; Rash on the injection site, rash has gotten bigger; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PRURITUS (Itching) and VACCINATION SITE RASH (Rash on the injection site, rash has gotten bigger) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PRURITUS (Itching) and VACCINATION SITE RASH (Rash on the injection site, rash has gotten bigger). At the time of the report, VACCINATION SITE PRURITUS (Itching) and VACCINATION SITE RASH (Rash on the injection site, rash has gotten bigger) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment medications were provided by the reporter.
Information has been received from a pharmacist via a company representative referring to a female patient of unknown age. Medical history and concurrent condition of the patient were not reported. On 10-DEC-2015 the patient was vaccinated with a dose of ZOSTAVAX, (lot#, expiration date and dose not reported), subcutaneously. On 11-DEC-2015 the patient called the pharmacist stating she had soft ball size redness and hardening at site of the injection developing on an unspecified date in December 2015. The patient was administered BENADRYL (manufacturer unspecified) as treatment. The outcome of the events was unknown. Additional information has been requested.
This case was reported by a consumer via other manufacturer and described the occurrence of injection site tenderness in a 57-year-old male patient who received Herpes zoster (Shingrix) (batch number 23JKS, expiry date 13th April 2020) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 20th April 2019, Lot:MX2LT, expiry date:21st May 2021). Concurrent medical conditions included type ii diabetes mellitus. Additional patient notes included Ethnicity-Caucasian. On 15th June 2019, the patient received the 2nd dose of Shingrix. On 15th June 2019, unknown after receiving Shingrix, the patient experienced drug dose administration interval too short. On an unknown date, the patient experienced injection site tenderness and injection site swelling. On an unknown date, the outcome of the injection site tenderness and injection site swelling were recovered/ resolved and the outcome of the drug dose administration interval too short was unknown. It was unknown if the reporter considered the injection site tenderness and injection site swelling to be related to Shingrix. Additional details were provided as follows: The case was reported by patient himself. The age at vaccination was not reported. The patient received 2nd dose of Shingrix vaccine and experienced injection site tenderness and swelling.  From March 2021, patient had current conditions of high blood pressure, type 2 diabetes mellitus and abscess. The patient had Covid in March 2020 and was not able to get tested in March 2020, but he had an antibody test in July2020 that confirmed he had it. Since 8th March 2021, the patient was on concomitant products Lisinopril (Dosage may had started a little lower) and from October 2021, Ozempic (0.25mg once a week, then was increased to 0.5mg once a week). On 11th March 2021, patient received 1st dose of Pfizer BioNtech Covid 19 vaccine, Lot: EN6204. On 1st April 2021, patient received 2nd dose of Pfizer BioNtech Covid 19 vaccine, Lot: ER8737 and 3rd dose received on 2nd December 2021, Lot: 33030BD, Expiry date : 31st May 2022. The patient had a noticeably stronger immune response with the Covid and Shingrix vaccines than with any other vaccine. The patient reported that had a full on natural exposure of Covid, the side effects are better than having the illness itself.
no additional AEs,; RN calling to report that expired lot of PNEUMOVAX 23 was administered on 3/7/2023 and requests information for revaccination recommendations. No further information provided, no additional AEs, no PQCs. LOT U026796 EXP 1/28/2023; This spontaneous report as received from a registered nurse concerning a 71-year-old patient, gender unspecified. There was no information about the patient's medical history, concurrent conditions or concomitant medication.  On 07-MAR-2023 the patient was vaccinated with an expired dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23), prefilled syringe, dose: 0.5 milliliter, frequency reported as once (0.5ml/once), lot # U026796, expiration date: 28-JAN-2023  for prophylaxis (Expired product administered)(route unspecified).    No further information provided, no additional adverse events, no PQCs.
Left upper arm swelling, pain, redness, warm to the touch at injection site.  Observation.  Allergy to drug in contact with skin, this maybe more of a local irritative reaction rather than a true allergy, but should not receive another shingrix injection.  No cellulitis.
Breakthrough case after 4 vaccines  Pfizer 3/11/21 Lot# EN6207;  Pfizer 4/1/21 Lot# Er8732;  Pfizer 10/6/21 Lot# 301308A;  Moderna 4/10/22 Lot# 046L21A
I did not have an adverse reaction to the vaccination. I felt like I had bad cold on 02/15/2023. I believe I was exposed to COVID-19 from my dentist office. I tested positive for COVID-19 on 02/15/2023. I contacted my doctor and got a prescription for Paxlovid. I tolerated the medication without any complications. As of today, I do not have any lingering symptoms.
I have a friend that facial swelling on 1 side of her face.; This spontaneous case was reported by a patient family member or friend and describes the occurrence of SWELLING FACE (I have a friend that facial swelling on 1 side of her face.) in a female patient of an unknown age who received mRNA-1273 (Spikevax) (batch no. ASKU) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced SWELLING FACE (I have a friend that facial swelling on 1 side of her face.). At the time of the report, SWELLING FACE (I have a friend that facial swelling on 1 side of her face.) had resolved.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant information was reported. It was reported that, patient had facial swelling on 1 side of her face, after her shot too. Patient didn't get the booster either. No treatment information was reported.   Reporter did not allow further contact
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 20-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Oct-2021 at 11:26 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 27-Oct-2021, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. Age of patient was reported as 20.47 for dose administered on 27-Oct-2021.  Batch number 035C21A underwent temperature excursion on 27-Oct-2021 with temperature 29 degrees Fahrenheit and 32 degrees Fahrenheit from 9:00 AM to 10:00 AM. This vial was moved to fridge on 29-Sep-2021 and 05-Oct-2021 and beyond use date for the vial was reported as 29-Oct-2021 and 04-Nov-2021. Product moved to clinic on 27-Oct-2021. Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour. No treatment medications were reported.     This case was linked to MOD-2022-566976 (Patient Link).
Information has been received from a physician concerning a 20 weeks and 5 days old patient who on 23-JUL-2010 was vaccinated orally with the first 2ml dose of ROTATEQ (lot # reported as 1507Y). The physician stated that she thought the patient already had the first dose of ROTATEQ so she administered a dose today (23-JUL-2010). After giving the dose to the patient, she realized the patient that was 20 weeks and 5 days old and never received the first dose. The patient was fine at this time. No medical attention was sought. At the time of this report, the patient's outcome was unknown. Additional information has been requested.
After receiving the Pfizer Covid 2nd shot. After two weeks my injection site has serious pain and is having an effect on normal operation.
ADACEL was administered with a 27 gauge 1/2" needle at a 90 degree angle.
In addition to general flu-like symptoms I had heart pain and pain to my spleen. These lasted for about 24 hours from onset of symptoms which began 12 hours after receiving my vaccine. The lymph nodes under the arm of my injection site were also swollen and painful to the touch or pressure such as sleeping on my side. I also had very unusual and vivid dreams the night of my shot which I am still able to recall days later.
Generalized rash - urticaria within 2 hours - spread to entire body treated with Prednisone and antihistamines.
This spontaneous report received from a physician, refers to a 35 year old female patient, with allergic rash to an unspecified hepatitis B vaccine There were not other pertinent medical history. On 08-JUN-2015 the patient was vaccinated with VAQTA 25/0.5 (units not reported) (dosage, route, lot # and expiration date were not reported). There were no concomitant therapies. On 09-JUN-2015, the patient experienced vertigo, feeling abnormal and dizziness, reported as "dizziness, mild vertigo problems with depth perception and felt like she was in a fog". The patient sought medical attention calling the physician, no treatment was prescribed and the patient did not recovered at the time of this report. There were not laboratories diagnostics performed.  Also was reported that the patient was scheduled for an appointment with the physician on 17-JUN-2015. This is one of several reports received from the same reporter. Additional information has been requested.
After the 2nd vaccine, patient was diagnosed with a rare malanoma in her vagina.  Started treatment for cancer. Got booster on 9/18/2021 (Pfizer, Lot # FF2588). Hospitalized with heart problem , eratic heartbeat. Fluxuating suger number. Diagnosed with mayocarditis. and septis.
Information has been received from a physician concerning a 1 year old female with bronchiolitis who on 30-NOV-2007 was vaccinated with a dose of MMR (no lot number was provided). "On 17-DEC-2007 the patient experienced bronchitis and was sent to the hospital with high fever and seizures. Length of time at the hospital was unknown." Subsequently, the patient recovered. There was no product quality complaint. The physician noted that he "believed that this adverse reaction did have any relation to MMR and was due to patient having bronchiolitis." Upon internal review, seizures were determined to be an other important medical event. Additional information has been requested.
Vaccine recipient intended to receive J&J Covid Booster dose and received Pfizer booster instead.  No adverse reaction observed at this time.
Discharge Physician: MD Primary Care Clinician at Discharge:  Admission Date: 6/9/2022 Discharge Date: 6/11/2022  PRESENTING PROBLEM: Orthostatic hypotension Generalized weakness COVID-19 virus infection   HOSPITAL COURSE: 69-year-old woman with chronic systolic heart failure (EF 23%), ischemic cardiomyopathy, coronary artery disease with ICD, mitral regurgitation (severe) and CKD stage 4 presented to the hospital with generalized weakness.  She is found to be orthostatic we positive and was given judicious fluid boluses in the emergency department given her heart failure.  She remained orthostatic and symptomatic and thus was admitted to the medical service.  COVID-19 testing was positive though she was asymptomatic and without hypoxemia on ambient air.  Review of medical records revealed that she was on hydrochlorothiazide/spironolactone/torsemide as well as lisinopril as prescribed by a Heart Clinic.  These medications were held and the patient was provided very judicious IV fluid hydration overnight.  Cardiac monitoring revealed no acute malignant arrhythmias.  Electrolytes were within normal limits and creatinine was at baseline.  Her symptoms did resolve.  Measured orthostatic vital signs did reveal resolution of orthostatic hypotension.  She was discharged on 06/11/2022.  She was instructed to hold hydrochlorothiazide until her next visit with a Heart Clinic.  She was discharged in good condition.
Received 1st SHINGRIX shot Nov. 4th, 2018. Suffered usual arm soreness (moderately - severe), tiredness and nausea. Lasted about 4-5 days. Approx. 2 wks later went to Doctor (Nov. 14th?) with swelling along left side of neck. Now has spread to both sides.
high temperature; Nausea; chills; dizziness; achiness; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (high temperature), NAUSEA (Nausea), CHILLS (chills), DIZZINESS (dizziness) and MYALGIA (achiness) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no medical history was reported).    On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, the patient experienced PYREXIA (high temperature), NAUSEA (Nausea), CHILLS (chills), DIZZINESS (dizziness) and MYALGIA (achiness). At the time of the report, PYREXIA (high temperature), NAUSEA (Nausea), CHILLS (chills), DIZZINESS (dizziness) and MYALGIA (achiness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
lethargic, no temp @ 4PM; threw up chills had a sz about 5PM; stopped breathing-transfered to cardiac intensive care unit; rash on chest; t105;
Dizziness; not able to stand; vomiting; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: er2613) via an unspecified route of administration in the left arm on 27MAr2021 at 16:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history reported. The patient previously had pollen allergy. The patient did not receive any concomitant medication. The patient previously received the first dose of BNT162b2 (PFIZER COVID-19 mRNA VACCINE BIONTECH, Lot number: en6205) via an unspecified route of administration in the left arm on 06Mar2021 at 04:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Mar2021, the patient experienced dizziness, vomiting, and difficulty in standing 6 hours after vaccination (at 22:00). The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events dizziness, vomiting, and difficulty in standing was recovered on an unknown date at the time of report.    No follow-up attempts are needed. No further information is expected.
Taste of formaldehyde for two days. Extreme pain in neck. Could not lift or turn head. Strep throat.
Redness noted to left thigh approximately 3-4" in diameter on 09/17/09. Ice pack applied to area, instructed mother to use BENADRYL for itching and to return to clinic if worsen. 9/18/09 - MD Appt. See attached 9/24/09 - spoke with mother - she stated child is fine. Patient had the DTaP shot to the left thigh the day before the appearance of the rash. Mom says the redness was warm yesterday and she put ice onto the thigh. No fever or respiratory distress during this time. No tenderness to the thigh. Patient is able to walk.
Pt vaccinated with Pneumococcal 23/Influenza developed aching over body in PM; temp 101+ lasting 1&1/2 days; arm extremely sore x 3 days. At end of 2nd day, developed rash over upper arm which lasted 3 days.
onset of URI symptoms on 07/12/2021 with a positive covid-19 test result, 07/13/2021
EXPIRED PRODUCT ADMINISTERED TO UNKNOWN NUMBER OF RESIDENTS; This spontaneous report received from a health care professional concerned multiple patients.  No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805031, expiry: UNKNOWN) dose, start therapy date were not reported for prophylactic vaccination. No concomitant medications were reported. On an unspecified date, the subject experienced expired product administered to unknown number of residents. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of expired product administered to unknown number of residents was not reported. This report was non-serious.
I was experiencing dizziness and occasional falling with hypotension in my blood pressure. My pressure was 58/36. I went hospital and stayed for 3 days. I went into AFIB though my pressure had returned to normal. I was told this was caused by abiraterone. I was given a loop recorder that will notify me of any future events. It was surgically inserted and provides constant monitoring. I went off abiraterone and prednisone and got onto ELIQUIS to prevent blood clots. I have not had an event since then.